DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
Medtronic has won FDA approval for a device that can help with therapy for those suffering from Parkinson’s Disease. The Dublin-based company’s BrainSense Adaptive deep brain stimulation (aDBS) and ...
The FDA approved Medtronic's BrainSense Adaptive DBS for Parkinson's, offering personalized therapy through automatic adjustments to patients' needs. The ADAPT-PD trial validated aDBS's safety and ...
Deep brain stimulation, a process in which electrodes stimulate specific brain circuits to reduce motor symptoms, has long helped people with Parkinson’s disease manage their tremors — but a new ...
MINNEAPOLIS, Minnesota — The U.S. Food and Drug Administration approved a Medtronic deep brain stimulation treatment to treat obsessive compulsive disorder – the first deep brain stimulation treatment ...
In 2003, Medtronic first received a humanitarian green light from the FDA to offer its deep brain stimulation implants to treat the symptoms of dystonia—the painful movement disorder that can cause ...
MINNEAPOLIS--(BUSINESS WIRE)-- In the largest, randomized, controlled study of deep brain stimulation (DBS) for Parkinson’s disease, Medtronic DBS Therapy was shown to improve motor function for up to ...
The technology is designed to adjust therapy in real time based on a patient’s brain activity, potentially improving symptom control, according to a Feb. 24 news release from the company. The ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results